Morgan Stanley raised the firm’s price target on Evommune (EVMN) to $55 from $54 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVMN:
- Evommune Earns Buy Rating on Late-Stage Pipeline Progress and Multiple Near-Term Clinical Catalysts
- Evommune reports Q1 EPS (64c), consensus (71c)
- Evommune Highlights Q1 Results and Advancing Inflammation Pipeline
- Evommune initiated with a Buy at Stifel
- Evommune’s EVO756 Phase 2b Trial: An Emerging Catalyst in Atopic Dermatitis